A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...
Vietnam Investment Review on MSN
Lynk Pharma reports positive phase III results for Zemprocitinib in RA
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development ...
Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...
Difficult-to-treat rheumatoid arthritis (D2T-RA) affects approximately 1 in 9 patients with RA worldwide, with nearly half of these cases demonstrating persistent inflammatory refractory RA (PIRRA), ...
A plant used in Brazilian medicine has scientific potential to help people with arthritis and other inflammatory conditions. Researchers tested Joseph’s Coat (Alternanthera littoralis) in lab studies ...
Rheumatoid arthritis is one of the chronic diseases caused by inflammation. It’s a painful, life-altering condition — and recently, the FDA approved a new treatment for it that Dr. John Tesser says ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. CAR-T therapy was originally developed for ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. In the past 5 years, PANLAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback